On July 27, 2023, molecular professionals from around the United States met with the offices of their elected representatives to express opposition to the Patent Eligibility Restoration Act of 2023. This concerning legislation would reverse a unanimous 2013 Supreme Court decision that has led to a decade of unprecedented scientific innovations and aided the U.S. testing response to the COVID-19 pandemic.
Samuel Caughron and Timothy J. O'Leary, members of the AMP COVID Response Steering Committee, explore different types of tests available to consumers as the fall flu season approaches.
Karen L. Kaul, MD, PhD, a member of the AMP COVID Response Steering Committee, provides an assessment on how in-system labs were instrumental in keeping institutions functioning and solvent during the pandemic.
Donna M. Wolk, PhD, Chair of the AMP Infectious Diseases Subdivision, shares a quick checklist for organizations looking to contract a clinical laboratory for COVID-19 screening testing as part of its reopening strategy.
Blake Buchan, AMP representative on the recent joint IDSA-AMP Statement regarding the use of SARS-CoV-2 PCR cycle threshold (Ct) values for clinical decision-making, provides insights as to why the practice is not advised at the current time.
Jordan Laser, Vice-Chair of AMP's Professional Relations Committee, provides an update on the White House announcement for increased funding for COVID-19 testing.
Frederick S. Nolte, Chair of the AMP COVID Response Steering Committee, weighs in on urgent actions needed as of February 2021 to combat the novel coronavirus.
Shortly before passing the Presidential baton at the 2020 AMP Annual Meeting & Expo, Karen Weck reflects on her term and AMP's COVID-19 response